Exendin-9,39

BIOLOGICAL6 trials

Sponsors

Mayo Clinic, Adrian Vella

Conditions

DiabetesHealthyObesityRoux-en-Y Gastric BypassType 2 DiabetesType 2 Diabetes Mellitus

Phase 1

A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake

CompletedNCT02128581

Mayo ClinicDiabetes, Obesity, Roux-en-Y Gastric Bypass

Start: 2014-05-31End: 2019-07-31Updated: 2019-10-23

Phase 2

The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes

CompletedNCT02762708

Mayo ClinicObesity, Type 2 Diabetes Mellitus

Start: 2016-03-31End: 2018-01-06Updated: 2022-05-03

Phase 3

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

CompletedNCT04459338

Adrian VellaHealthy

Start: 2021-03-04End: 2022-06-14Updated: 2023-06-09

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

CompletedNCT04466618

Adrian VellaHealthy, Type 2 Diabetes

Start: 2021-04-15End: 2022-12-31Updated: 2023-12-26

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

CompletedNCT04466566

Adrian VellaHealthy

Start: 2022-10-17End: 2025-12-30Updated: 2026-01-22

Unknown Phase

Exendin-9,39 and Satiety After Bariatric Surgery

CompletedNCT02779075

Mayo ClinicObesity

Start: 2016-06-30End: 2019-12-31Updated: 2020-05-01

Related Papers

Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans

Journal of Clinical Investigation2023-09-269 citations

A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery

Metabolic Syndrome and Related Disorders2020-08-244 citations